BACKGROUND: Sustained pressure overload of the right ventricle (RV) causes RV hypertrophy and failure. Cyclic-GMP has previously been shown to modulate left ventricular hypertrophy. AIM: To evaluate the effects of sildenafil, a phosphodiesterase-5 (PDE5) inhibitor elevating c-GMP, on myocardial hypertrophy and function in rats with RV hypertrophy. METHODS: Rats were pulmonary trunk banded (PTB) and randomized to receive sildenafil (SIL) or vehicle (VEC) for three (n=14) and nine weeks (n=18). In addition, rats with established RV hypertrophy were randomized to SIL or VEC (n=17) three weeks after PTB. Right ventricular function was evaluated by echocardiography and RV hypertrophy by histology and RV weight. RESULTS: Sildenafil failed to inhibit the development of RV hypertrophy when given for both 3 and 9 weeks. On the contrary, sildenafil increased RV hypertrophy after 3 weeks (RV/bodyweight: SIL 0.099+/-0.016 vs. VEC 0.081+/-0.011; p<0.05) and total heart weight after 9 weeks (SIL 1.05+/-0.10 vs. VEC 0.93+/-0.08 g; p<0.05). Sildenafil also failed to reverse established RV hypertrophy, but significantly improved RV myocardial function as measured by Tricuspid Annular Plane Systolic Excursion (TAPSE: SIL 1.85+/-0.027 vs. VEC 1.39+/-0.037 mm; p<0.05). CONCLUSION: PDE5 inhibition by sildenafil failed to prevent or reverse RV hypertrophy in rats operated by pulmonary trunk banding. It actually increased RV hypertrophy and improved RV contractile function when given to rats with established RV hypertrophy.
BACKGROUND: Sustained pressure overload of the right ventricle (RV) causes RV hypertrophy and failure. Cyclic-GMP has previously been shown to modulate left ventricular hypertrophy. AIM: To evaluate the effects of sildenafil, a phosphodiesterase-5 (PDE5) inhibitor elevating c-GMP, on myocardial hypertrophy and function in rats with RV hypertrophy. METHODS:Rats were pulmonary trunk banded (PTB) and randomized to receive sildenafil (SIL) or vehicle (VEC) for three (n=14) and nine weeks (n=18). In addition, rats with established RV hypertrophy were randomized to SIL or VEC (n=17) three weeks after PTB. Right ventricular function was evaluated by echocardiography and RV hypertrophy by histology and RV weight. RESULTS:Sildenafil failed to inhibit the development of RV hypertrophy when given for both 3 and 9 weeks. On the contrary, sildenafil increased RV hypertrophy after 3 weeks (RV/bodyweight: SIL 0.099+/-0.016 vs. VEC 0.081+/-0.011; p<0.05) and total heart weight after 9 weeks (SIL 1.05+/-0.10 vs. VEC 0.93+/-0.08 g; p<0.05). Sildenafil also failed to reverse established RV hypertrophy, but significantly improved RV myocardial function as measured by Tricuspid Annular Plane Systolic Excursion (TAPSE: SIL 1.85+/-0.027 vs. VEC 1.39+/-0.037 mm; p<0.05). CONCLUSION: PDE5 inhibition by sildenafil failed to prevent or reverse RV hypertrophy in rats operated by pulmonary trunk banding. It actually increased RV hypertrophy and improved RV contractile function when given to rats with established RV hypertrophy.
Authors: Leroy L Cooper; Katja E Odening; Min-Sig Hwang; Leonard Chaves; Lorraine Schofield; Chantel A Taylor; Anthony S Gemignani; Gary F Mitchell; John R Forder; Bum-Rak Choi; Gideon Koren Journal: Am J Physiol Heart Circ Physiol Date: 2012-02-03 Impact factor: 4.733
Authors: Mads D Vildbrad; Asger Andersen; Sarah Holmboe; Steffen Ringgaard; Jan M Nielsen; Jens Erik Nielsen-Kudsk Journal: Pulm Circ Date: 2014-09 Impact factor: 3.017
Authors: Yu-Ping Xie; Biyi Chen; Philip Sanders; Ang Guo; Yue Li; Kathy Zimmerman; Lie-Cheng Wang; Robert M Weiss; Isabella M Grumbach; Mark E Anderson; Long-Sheng Song Journal: Hypertension Date: 2011-12-27 Impact factor: 10.190
Authors: Xiaoyin Shan; Michael P Quaile; Jeffery K Monk; Benjamin French; Thomas P Cappola; Kenneth B Margulies Journal: Circ Heart Fail Date: 2011-12-01 Impact factor: 8.790
Authors: Rachel P Heilman; Megan B Lagoski; Keng Jin Lee; Joann M Taylor; Gina A Kim; Sara K Berkelhamer; Robin H Steinhorn; Kathryn N Farrow Journal: Am J Physiol Heart Circ Physiol Date: 2015-04-10 Impact factor: 4.733
Authors: Sarah Holmboe; Asger Andersen; Mads D Vildbrad; Jan M Nielsen; Steffen Ringgaard; Jens E Nielsen-Kudsk Journal: Pulm Circ Date: 2013-12 Impact factor: 3.017